Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.

Sanoff, Hanna K; Kim, Richard; Ivanova, Anastasia; Alistar, Angela; McRee, Autumn J; O'Neil, Bert H

Sanoff, Hanna K; Kim, Richard; Ivanova, Anastasia; Alistar, Angela; McRee, Autumn J; O'Neil, Bert H.

Affiliation

Sanoff HK; Division of Hematology and Oncology, University of North Carolina at Chapel Hill, 170 Manning Drive, CB 7305, Chapel Hill, NC, 27599, USA, hanna_sanoff@med.unc.edu.

Invest New Drugs ; 33(2): 505-9, 2015 Apr.

Article in En | MEDLINE | ID: mdl-25613083

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carcinoma, Hepatocellular/drug therapy; Everolimus/therapeutic use; Liver Neoplasms/drug therapy; Somatostatin/analogs & derivatives; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Disease-Free Survival; Everolimus/administration & dosage; Everolimus/adverse effects; Female; Humans; Male; Middle Aged; Response Evaluation Criteria in Solid Tumors; Somatostatin/administration & dosage; Somatostatin/adverse effects; Somatostatin/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Somatostatin / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Hepatocellular / Everolimus / Liver Neoplasms Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2015 Type: Article

Fulltext

XML

PubMed Links

Search on Google